E
Eleonora Sementino
Researcher at Fox Chase Cancer Center
Publications - 22
Citations - 1319
Eleonora Sementino is an academic researcher from Fox Chase Cancer Center. The author has contributed to research in topics: BAP1 & Mesothelioma. The author has an hindex of 10, co-authored 16 publications receiving 1097 citations. Previous affiliations of Eleonora Sementino include University of Perugia.
Papers
More filters
Journal ArticleDOI
Germline BAP1 mutations predispose to malignant mesothelioma
Joseph R. Testa,Mitchell Cheung,Jianming Pei,Jennifer E. Below,Yinfei Tan,Eleonora Sementino,Nancy J. Cox,A. Umran Dogan,A. Umran Dogan,Harvey I. Pass,Sandra Trusa,Mary Hesdorffer,Masaki Nasu,Amy Powers,Zeyana Rivera,Sabahattin Cömertpay,Mika Tanji,Giovanni Gaudino,Haining Yang,Michele Carbone +19 more
TL;DR: A BAP1-related cancer syndrome is identified that is characterized by mesothelioma and uveal melanoma, and it is hypothesized that other cancers may also be involved and that mesot helioma predominates upon asbestos exposure.
Journal ArticleDOI
Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma
Jinfei Xu,Yuwaraj Kadariya,Mitchell Cheung,Jianming Pei,Jacqueline Talarchek,Eleonora Sementino,Yinfei Tan,Craig W. Menges,Kathy Q. Cai,Samuel Litwin,Hongzhuang Peng,Jayashree Karar,Frank J. Rauscher,Joseph R. Testa +13 more
TL;DR: Unbiased genetic findings indicate that BAP1 mutation carriers are predisposed to the tumorigenic effects of asbestos and suggest that high penetrance of mesothelioma requires such environmental exposure.
Journal ArticleDOI
Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations.
Yuwaraj Kadariya,Mitchell Cheung,Jinfei Xu,Jianming Pei,Eleonora Sementino,Craig W. Menges,Kathy Q. Cai,Frank J. Rauscher,Andres J. Klein-Szanto,Joseph R. Testa +9 more
TL;DR: Findings provide genetic evidence that Bap1 is a bona fide tumor suppressor gene and offer key insights into the contribution of carcinogen exposure to enhanced cancer susceptibility.
Journal ArticleDOI
Group I p21-Activated Kinases (PAKs) Promote Tumor Cell Proliferation and Survival through the AKT1 and Raf–MAPK Pathways
Craig W. Menges,Eleonora Sementino,Jacqueline Talarchek,Jinfei Xu,Jonathan Chernoff,Jeffrey R. Peterson,Joseph R. Testa +6 more
TL;DR: It is suggested that pharmacologic inhibition of group I PAKs may have therapeutic efficacy in tumors characterized by PAK activation and that inhibition of PAK results in attenuation of AKT and Raf–MAPK signaling and decreased tumor cell viability.
Journal ArticleDOI
Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.
Anna-Mariya Kukuyan,Eleonora Sementino,Yuwaraj Kadariya,Craig W. Menges,Mitchell Cheung,Yinfei Tan,Kathy Q. Cai,Michael Slifker,Suraj Peri,Andres J. Klein-Szanto,Frank J. Rauscher,Joseph R. Testa +11 more
TL;DR: It is demonstrated that somatic inactivation of Bap1, Nf2, and Cdkn2a results in rapid, aggressive MMs, and that deletion of BAP1 contributes to tumor development, in part, by loss of PRC2-mediated gene repression of tumorigenic target genes and by acquisition of stem-cell potential, suggesting a potential avenue for therapeutic intervention.